The government has been focused on the biotechnology industry since 1984, when it set up a biotechnology and pharmaceutical industry development promotion task force. In 2007, it passed the Act for the Development of Biotech and New Pharmaceuticals Industry (生技新藥產業發展條例), and following the outbreak of the COVID-19 pandemic last year, the biotech industry has garnered even more attention.
FAILED PROGRAMS
However, a look at the “two trillion, twin star” program in 2002, the “six key emerging industries” program in 2009, the “5+2 industrial innovation” program in 2016 and last year’s “six core strategic industries” program shows that there has been progress in the industry, but not as much as expected.
The industry has not driven economic development in the same way that the semiconductor industry did, and insufficient international integration has failed to produce world-class companies or unicorns and it cannot compare with South Korea’s beauty and biotech OEM industries.
The value of Taiwan’s biotech industry is less than NT$600 billion (US$21.39 million), and it has only created about 100,000 job opportunities. There are several reasons for the limited results over the past four decades.
First, Taiwan’s social welfare environment and regulations are not conducive to the industry’s development, as healthcare is based on a non-profit policy. This is different from the semiconductor and other industries, which are mainly for-profit.
Second, many biotech firms had insufficient revenue and profit, but chose to list as “category 3 stocks” (now classified as tech stocks). They used publicity and speculation to attract funds from capital markets, while the government provided incentives in the form of rent and tax subsidies.
The result is that some biotech firms took shortcuts and speculated in stock. Moreover, a lack of capital and research and development talent made wide-scale human testing difficult, while insufficient international integration made building a complete supply chain a challenge.
Third, a lack of understanding of foreign pharmaceutical companies, difficulties obtaining information, incomplete understanding of regulations in other countries, differences in interpretation of provisions and disputes over agency or cooperation contracts often resulted in losses for local pharmaceutical and biotech companies that intend to enter the international market. Worse still, the authorities overseeing stock exchanges did not verify unclear information from other countries and imposed severe penalties, making matters worse.
VITAL ISSUES
The biotech industry faces many challenges. How can regulations be relaxed for the industry to facilitate cooperation with the high-tech industry, academics, development institutions and the medical sector? How will it raise capital, cultivate talent, create a complete supply chain and become a functional industry developing high-end biotech medicine and health and medical equipment? How will it tap into the distinct characteristics of individual markets to venture into the international market? How will it do these things with the support of the government and fair treatment from regulators, thus creating a new benchmark industry?
These are important issues that must be addressed by the industrial, government, academic, research and healthcare sectors.
Lee Shen-yi is a national policy adviser and vice chairman of the Contemporary Taiwan Development Foundation.
Translated by Perry Svensson
Chinese state-owned companies COSCO Shipping Corporation and China Merchants have a 30 percent stake in Kaohsiung Port’s Kao Ming Container Terminal (Terminal No. 6) and COSCO leases Berths 65 and 66. It is extremely dangerous to allow Chinese companies or state-owned companies to operate critical infrastructure. Deterrence theorists are familiar with the concepts of deterrence “by punishment” and “by denial.” Deterrence by punishment threatens an aggressor with prohibitive costs (like retaliation or sanctions) that outweigh the benefits of their action, while deterrence by denial aims to make an attack so difficult that it becomes pointless. Elbridge Colby, currently serving as the Under
The Ministry of the Interior on Thursday last week said it ordered Internet service providers to block access to Chinese social media platform Xiaohongshu (小紅書, also known as RedNote in English) for a year, citing security risks and more than 1,700 alleged fraud cases on the platform since last year. The order took effect immediately, abruptly affecting more than 3 million users in Taiwan, and sparked discussions among politicians, online influencers and the public. The platform is often described as China’s version of Instagram or Pinterest, combining visual social media with e-commerce, and its users are predominantly young urban women,
Most Hong Kongers ignored the elections for its Legislative Council (LegCo) in 2021 and did so once again on Sunday. Unlike in 2021, moderate democrats who pledged their allegiance to Beijing were absent from the ballots this year. The electoral system overhaul is apparent revenge by Beijing for the democracy movement. On Sunday, the Hong Kong “patriots-only” election of the LegCo had a record-low turnout in the five geographical constituencies, with only 1.3 million people casting their ballots on the only seats that most Hong Kongers are eligible to vote for. Blank and invalid votes were up 50 percent from the previous
Japanese Prime Minister Sanae Takaichi lit a fuse the moment she declared that trouble for Taiwan means trouble for Japan. Beijing roared, Tokyo braced and like a plot twist nobody expected that early in the story, US President Donald Trump suddenly picked up the phone to talk to her. For a man who normally prefers to keep Asia guessing, the move itself was striking. What followed was even more intriguing. No one outside the room knows the exact phrasing, the tone or the diplomatic eyebrow raises exchanged, but the broad takeaway circulating among people familiar with the call was this: Trump did
RSS